Lingji Taixiang, a subsidiary of Dongfang Baitai, has been recognized as a Beijing Intellectual Property Demonstration Unit.
[Summary Description]
Recently, the Beijing Intellectual Property Bureau announced the “List of Beijing Intellectual Property Pilot and Demonstration Units for 2022.” Beijing Jingyitai Xiang Technology Development Co., Ltd., which specializes in the research, development, and production of innovative antibody drugs, was officially recognized as a “Beijing Intellectual Property Demonstration Unit” thanks to its strong R&D capabilities and a well‑established intellectual property management system.
Autumn is the season of harvest.
Innovation has always been the most distinctive hallmark of Dongfang Baitai.
Rowing vigorously and hoisting the sails, we chase our dreams and forge ahead.
Jingyi Taixiang, a wholly owned subsidiary of Dongfang Baitai, has been recognized as…
Beijing Intellectual Property Demonstration Unit
Reaping the good news of autumn, we forge ahead on a new journey and write a new chapter.

Recently, the Beijing Intellectual Property Bureau announced the “List of Beijing Intellectual Property Pilot and Demonstration Units for 2022.” Beijing Jingyitai Xiang Technology Development Co., Ltd., which specializes in the research, development, and production of innovative antibody drugs, was officially recognized as a “Beijing Intellectual Property Demonstration Unit” thanks to its strong R&D capabilities and a well‑established intellectual property management system.

Beijing Jingyi Taixiang Technology Development Co., Ltd. (hereinafter referred to as Jingyi Taixiang) is a wholly owned subsidiary of Beijing Dongfang Baitai Biotechnology Co., Ltd. (hereinafter referred to as Dongfang Baitai). Over the years, Jingyi Taixiang has regarded research and development and innovation as its primary productive force, leveraging the respective platform strengths of both companies to introduce advanced instruments and continuously advance and refine basic research, evidence-based science, and the exploration of cutting-edge manufacturing processes, striving to achieve steady and sustainable progress and make meaningful contributions in the field of antibody drug development.
In 2022, the evaluation of Beijing’s intellectual property pilot and demonstration units was conducted through several stages, including preliminary review by the intellectual property bureaus of each district in Beijing, a secondary review by the Municipal Intellectual Property Bureau, and expert assessment. These processes comprehensively evaluated the applicant units’ capabilities in IP creation, management systems, utilization, and protection, ultimately resulting in the selection of an official list of recognized entities.
This time, Jingyi Taixiang has successfully been recognized as a “Beijing Intellectual Property Demonstration Unit,” reflecting the Beijing Municipal Intellectual Property Office’s acknowledgment and appreciation of the company’s innovative achievements, its sustained commitment to cutting-edge research, and its proactive intellectual property strategy—providing crucial support for the enterprise’s sustainable development.
In recent years, Dongfang Baitai and Jingyi Taixiang have consistently regarded intellectual property protection as an essential prerequisite for innovation-driven development, leveraging it as a fundamental engine to vigorously advance high-quality growth in the biopharmaceutical sector.

As the parent company of Jingli Taixiang, Dongfang Baitai places great emphasis on technological innovation and the commercialization of intellectual property. The company has established a dedicated intellectual property department and put in place a comprehensive IP management system, along with policies for patent administration and patent incentives, as well as an IP strategy and an IP‑portfolio planning framework, actively advancing internal institutional development. It has been recognized as both a “Beijing Intellectual Property Operation Pilot Unit” and a “Beijing Intellectual Property Demonstration Unit.” To date, the company has filed more than 100 patent applications, including invention patents in 18 countries and regions, such as the United States, Europe, Japan, South Korea, Australia, and Canada.
With unwavering determination and vigorous effort, we will advance steadily toward lasting success. Dongfang Baitai and Jingyi Taixiang will continue to pursue innovation-driven development and technology led by patents, closely aligning with both national priorities and the needs of the people, thereby empowering the upgrading of the biopharmaceutical industry, fostering a thriving biopharmaceutical ecosystem, uniting the strengths of the sector, and contributing to healthier lives for all.

Now is the time to forge ahead.
Continue to deepen our commitment to the biopharmaceutical industry.
Carrying beauty, safeguarding health
Strive to write new chapters of high-quality development.
A warm welcome to Vice Mayor Lin Keqing for his visit and guidance at Dongfang Baitai.
On October 24, 2016, Beijing Vice Mayor Lin Keqing and his delegation visited Beijing Dongfang Baitai Biotechnology Co., Ltd. and Baitai Bio-pharmaceutical Co., Ltd., conducted an in-depth review of the companies’ R&D progress, inspected the production workshops on-site, and engaged in cordial discussions.
Leave a Message Online Online Message